Business
Faron Announces Clevegen Grant of European Patent
Faron Announces Clevegen Grant of European Patent.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \nRNS Number : 5618D Faron Pharmaceuticals Oy 01 February 2018 \n\nFaron Pharmaceuticals Ltd\n(\"Faron\" or the \"Company\")\n \nFaron Announces Grant of European Patent for Clevegen\n \nPatent protects the use of Clevegen, the Company's second wholly-owned asset, for the treatment of cancer, until 2030\n \nTURKU - FINLAND, 1 February 2018 - Faron Pharmaceuticals Ltd (\"Faron\") (AIM: FARN), the clinical stage biopharmaceutical company, announces that the European Patent Office has granted Faron a European Patent (No. 2421888) for the use of Clever-1 antibodies, the mechanism behind Clevegen, for the treatment of cancer. Clevegen, Faron's second wholly-owned pipeline product, is a novel anti-Clever-1 antibody which causes changes in the immune environment of solid tumours by switching immune suppressive M2 macrophages to immune active M1 macrophages. Faron plans to initiate clinical Phase I/II Clevegen development in 2018.\n \nThe field of the patent invention is: an agent capable of modulating the Clever-1 receptor on the type 2 macrophage cell, that in addition to the mannose receptor, also expresses the Clever-1 receptor for use in the treatment of cancer.\n \nThis decision extends the existing patent estate for Clevegen until 2030. Additional IP around Clevegen's mechanism is being sought that could extend protection to the end of 2038.\n \nClevegen is based on Faron's Tumour Immunity Enabling Technology (TIET). Its unique mechanism of action, coupled with promising pre-clinical data and human ex-vivo data, has already indicated the product's potential in a broad range of indications. Clevegen's potential indications include immuno-oncology, chronic infections and vaccination enhancement, which all involve the presence of these same macrophages as immune suppressive cell type. As part of the stated strategy, Faron intends to expand its clinical trial program in order to broaden Clevegen's applicability and associated value.\n \nThe planned initial Phase I/II trial will target patients with liver, melanoma, ovarian and pancreatic cancer as part of an adaptive protocol design, which is currently under review by regulators, with feedback anticipated in 2018.\n \nMore details on Clevegen's manufacturing, regulatory and scientific progress, in addition to an update on the clinical ...